Clinical Trials Logo

Relapsed/Refractory Leukemia clinical trials

View clinical trials related to Relapsed/Refractory Leukemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT00780143 Terminated - Clinical trials for Relapsed/Refractory Leukemia

Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia

Start date: November 2007
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II study to determine the safety, tolerability and to identify the MTD and DLT of Plitidepsin in combination with a fixed dose of Cytarabine in patients with relapsed/refractory leukemia and to determine the response rate of the combination of Plitidepsin with Cytarabine in patients with relapsed/refractory AML treated at the MTD.

NCT ID: NCT00724360 Terminated - Clinical trials for Relapsed/Refractory Leukemia

Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)

Start date: November 2006
Phase: Phase 2
Study type: Interventional

This is a multicenter open-label phase II trial of trastuzumab in patients with HER2 positive B-ALL in relapse, or with refractory disease. Herceptin is administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or till progression. Response and HER2 expression are assessed each month by bone marrow aspirate.